Desensitization and resensitization of human platelets to 5-hydroxytryptamine at the level of signal transduction.
Desensitization of platelets to 5-hydroxytryptamine (5HT) (1 microM), during active removal of the agonist by the platelet 5HT-uptake system, was studied at the level of signal transduction. Desensitization to 5HT was dose-dependent and homologous. Without occupation of the 5HT2 receptor, neither an increase in cytosolic [Ca2+] (30 nM ionomycin), nor a separate or simultaneous activation of protein kinase C (by 10 microM 1-oleoyl-2-acetylglycerol), could induce desensitization to 5HT (1 microM). During the early phase of desensitization, the 5HT2 receptor was coupled to phospholipase C, whereas during the late phase of desensitization this coupling was disconnected. However, after disappearance of the agonist, the coupling in the resting platelet recovered quickly, and was nearly complete (82%) after 30 min. During this resensitization, the 5HT-inducibility of activation of phospholipase C, of the increase in cytosolic [Ca2+] and of stimulation of protein kinase C were restored in parallel. The time course for resensitization of the 5HT-induced increase in cytosolic [Ca2+] was independent of the presence of extracellular Ca2+. It is concluded that, after dissociation of 5HT from the platelet 5HT2-receptor, 5HT-induced responses rapidly resensitize. Because of its short duration and the parallelism in recovery between the different 'down-stream phospholipase C' intracellular transduction signals, it is considered that desensitization arises from a reversible change in the transduction mechanism at a step up to or including the activation of phospholipase C. Neither desensitization nor resensitization to 5HT is dependent on the presence of extracellular Ca2+.
Roevens
P
P
Department of Biochemistry, Janssen Research Foundation, Beerse, Belgium.
de Chaffoy de Courcelles
D
D
D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D004789:Enzyme Activation; D006801:Humans; D007700:Kinetics; D018377:Neurotransmitter Agents / Q000502:physiology; D011493:Protein Kinase C / Q000097:blood; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology*; D012680:Sensitivity and Specificity; D012701:Serotonin / Q000097:blood* / Q000493:pharmacokinetics / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology*; D010738:Type C Phospholipases / Q000097:blood
D018377:Neurotransmitter Agents; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D012701:Serotonin; D011493:Protein Kinase C; D010738:Type C Phospholipases